PARTNERING

PARTNERING WITH ASSEMBLY BIOSCIENCES

Assembly Biosciences is focused on discovering, developing, and commercializing a new class of oral therapeutics for chronic hepatitis B virus infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome.

The company possesses technologies and capabilities for characterizing and delivering these therapeutics. Its proven management team and intellectual property portfolio help our partners potentially deliver innovative treatments for improved patient care.

If your organization is interested in partnering with Assembly to develop, test, manufacture, or commercialize drug candidates, please contact BD@assemblybio.com.